NASDAQ:KURA

Kura Oncology Stock Forecast, Price & News

$23.37

+0.95 (+4.24 %)

(As of 06/14/2021 12:00 AM ET)

Add

Compare

Today's Range

$22.48

▼

$23.71

50-Day Range

$20.98

▼

$29.71

52-Week Range

$15.49

▼

$43.00

Volume955,193 shs

Average Volume720,612 shs

Market Capitalization$1.55 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.93

30 days | 90 days | 365 days | Advanced Chart

Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for Kura Oncology and its competitors with MarketBeat's FREE daily newsletter.

About Kura Oncology

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

Kura Oncology to Participate in JMP Securities Life Sciences Conference
June 10, 2021 | finance.yahoo.com

Kura Oncology Appoints Carol Schafer to Board of Directors
June 4, 2021 | ca.finance.yahoo.com

Kura Oncology Appoints Carol Schafer to Board of Directors
June 4, 2021 | finance.yahoo.com

Kura Oncology (NASDAQ:KURA) Trading Up 6.1%
May 25, 2021 | americanbankingnews.com

Kura Oncology (NASDAQ:KURA) Stock Price Down 4.2%
May 21, 2021 | americanbankingnews.com

Kura Oncology to Participate in Cowen Virtual Oncology Innovation Summit
May 13, 2021 | finance.yahoo.com

Kura Oncology, Inc. (KURA) Q1 2021 Earnings Call Transcript
May 7, 2021 | finance.yahoo.com

Kura Oncology Reports First Quarter 2021 Financial Results
May 6, 2021 | finance.yahoo.com

Kura Oncology to Report First Quarter 2021 Financial Results
April 29, 2021 | finance.yahoo.com

KURA Crosses Above Key Moving Average Level
April 1, 2021 | nasdaq.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KURA
Previous Symbol
CUSIPN/A
CIK1422143
Webwww.kuraoncology.com
Phone858-500-8800
Employees88
Year FoundedN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book Value$10.77 per share
Price / Book2.17

Profitability

EPS (Most Recent Fiscal Year)($1.69)
Net Income$-89,630,000.00
Net MarginsN/A
Return on Equity-22.15%
Return on Assets-20.63%

Debt

Price-To-Earnings

Miscellaneous

Outstanding Shares66,270,000
Market Cap$1.55 billion
Next Earnings Date8/5/2021 (Estimated)
OptionableOptionable

MarketRank^™

Overall MarketRank^™

1.23 out of 5 stars

Medical Sector

924th out of 2,100 stocks

Pharmaceutical Preparations Industry

449th out of 832 stocks

3.4 Analyst's Opinion

Consensus Rating
Kura Oncology has received a consensus rating of Buy. The company's average rating score is 2.89, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $42.56, Kura Oncology has a forecasted upside of 82.1% from its current price of $23.37.
Amount of Analyst Coverage
Kura Oncology has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Kura Oncology has received 367 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Kura Oncology has received 316 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Kura Oncology has received 53.73% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Kura Oncology and other stocks. Vote “Outperform” if you believe KURA will outperform the S&P 500 over the long term. Vote “Underperform” if you believe KURA will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Kura Oncology does not currently pay a dividend.
Dividend Growth
Kura Oncology does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Kura Oncology insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $183,938.00 in company stock.
Percentage Held by Insiders
Only 4.90% of the stock of Kura Oncology is held by insiders.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Kura Oncology are expected to decrease in the coming year, from ($2.04) to ($2.17) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Kura Oncology is -13.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Kura Oncology is -13.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Kura Oncology has a P/B Ratio of 2.17. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

Is Kura Oncology a buy right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last twelve months. There are currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Kura Oncology stock.
View analyst ratings for Kura Oncology or view top-rated stocks.

What stocks does MarketBeat like better than Kura Oncology?

Wall Street analysts have given Kura Oncology a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Kura Oncology wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Kura Oncology.

How were Kura Oncology's earnings last quarter?

Kura Oncology, Inc. (NASDAQ:KURA) issued its quarterly earnings results on Thursday, May, 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by $0.04.
View Kura Oncology's earnings history.

How has Kura Oncology's stock price been impacted by COVID-19?

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, KURA shares have increased by 142.2% and is now trading at $23.37.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for KURA?

9 analysts have issued 1 year target prices for Kura Oncology's shares. Their forecasts range from $33.00 to $56.00. On average, they expect Kura Oncology's stock price to reach $42.56 in the next year. This suggests a possible upside of 82.1% from the stock's current price.
View analysts' price targets for Kura Oncology or view top-rated stocks among Wall Street analysts.

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:

Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 52, Pay $908.26k)
Dr. Marc Grasso, CFO & Chief Bus. Officer (Age 48, Pay $630.86k)
Ms. Kathleen Ford, Chief Operating Officer (Age 74, Pay $492.28k)
Mr. James E. Basta J.D., Esq., Chief Legal Officer, Chief Compliance Officer & Corp. Sec. (Age 55, Pay $168.94k)
Mr. Pete De Spain, VP of Investor Relations & Corp. Communications
Dr. Blake Tomkinson M.B.A., Ph.D., Head of Portfolio Strategy & Program Management
Ms. Kirsten Flowers, Chief Commercial Officer (Age 46)
Dr. Roger Bakale Ph.D., VP and Head of CMC, Clinical & Commercial Manufacturing
Dr. Stephen Dale M.D., Chief Medical Officer (Age 49)
Dr. Nic G. Scalfarotto, Sr. VP of Regulatory Affairs

Who are some of Kura Oncology's key competitors?

Some companies that are related to Kura Oncology include TG Therapeutics (TGTX), Schrödinger (SDGR), Ionis Pharmaceuticals (IONS), Legend Biotech (LEGN), Reata Pharmaceuticals (RETA), I-Mab (IMAB), Galapagos (GLPG), Blueprint Medicines (BPMC), Allakos (ALLK), Apellis Pharmaceuticals (APLS), HUTCHMED (HCM), ACADIA Pharmaceuticals (ACAD), Hypera (HYPMY), Sage Therapeutics (SAGE) and Alkermes (ALKS).
View all of KURA's competitors.

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Amarin (AMRN), Gilead Sciences (GILD), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP) and Advanced Micro Devices (AMD).

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (7.88%), EcoR1 Capital LLC (5.57%), Ameriprise Financial Inc. (3.73%), Holocene Advisors LP (3.38%), Victory Capital Management Inc. (2.52%) and BVF Inc. IL (2.47%). Company insiders that own Kura Oncology stock include Antonio Gualberto, Kathleen Ford, Marc Grasso and Troy Edward Wilson.
View institutional ownership trends for Kura Oncology.

Which major investors are selling Kura Oncology stock?

KURA stock was sold by a variety of institutional investors in the last quarter, including RTW Investments LP, Credit Suisse AG, Nuveen Asset Management LLC, Goldman Sachs Group Inc., Federated Hermes Inc., D. E. Shaw & Co. Inc., Acuta Capital Partners LLC, and JPMorgan Chase & Co.. Company insiders that have sold Kura Oncology company stock in the last year include Kathleen Ford, Marc Grasso, and Troy Edward Wilson.
View insider buying and selling activity for Kura Oncology or view top insider-selling stocks.

Which major investors are buying Kura Oncology stock?

KURA stock was bought by a variety of institutional investors in the last quarter, including EcoR1 Capital LLC, Ameriprise Financial Inc., Holocene Advisors LP, Suvretta Capital Management LLC, BVF Inc. IL, BlackRock Inc., Ghost Tree Capital LLC, and Sphera Funds Management LTD..
View insider buying and selling activity for Kura Oncology or or view top insider-buying stocks.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $23.37.

How much money does Kura Oncology make?

Kura Oncology has a market capitalization of $1.55 billion. The company earns $-89,630,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

How many employees does Kura Oncology have?

Kura Oncology employs 88 workers across the globe.

What is Kura Oncology's official website?

The official website for Kura Oncology is www.kuraoncology.com.

Where are Kura Oncology's headquarters?

Kura Oncology is headquartered at 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 12730 HIGH BLUFF DRIVE SUITE 400, SAN DIEGO CA, 92130. The company can be reached via phone at 858-500-8800 or via email at [email protected]

This page was last updated on 6/15/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here